ATG9A Antibody Blocking peptide
€363.00
In stock
SKU
AC-BP1814e
Background:
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). Apg9 plays a direct role in the formation of the cytoplasm to vacuole targeting and autophagic vesicles, possibly serving as a marker for a specialized compartment essential for these vesicle-mediated alternative targeting pathways.
Other Names:
Autophagy-related protein 9A, APG9-like 1, mATG9, ATG9A, APG9L1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1814e was selected from the S613 region of human APG9L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ATG9A {ECO:0000303|PubMed:20124090, ECO:0000312|HGNC:HGNC:22408}
Gene ID: 79065
Primary Accession: Q7Z3C6
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). Apg9 plays a direct role in the formation of the cytoplasm to vacuole targeting and autophagic vesicles, possibly serving as a marker for a specialized compartment essential for these vesicle-mediated alternative targeting pathways.
Other Names:
Autophagy-related protein 9A, APG9-like 1, mATG9, ATG9A, APG9L1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1814e was selected from the S613 region of human APG9L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ATG9A {ECO:0000303|PubMed:20124090, ECO:0000312|HGNC:HGNC:22408}
Gene ID: 79065
Primary Accession: Q7Z3C6
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review